Cargando…

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing

Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing. Janus kinase (JAK) inhibition with tofacitinib has been demonstrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaber, Timo, Brinkman, Antonia Clara Katharina, Pienczikowski, Justyna, Diesing, Karoline, Damerau, Alexandra, Pfeiffenberger, Moritz, Lang, Annemarie, Ohrndorf, Sarah, Burmester, Gerd-Rüdiger, Buttgereit, Frank, Hoff, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037633/
https://www.ncbi.nlm.nih.gov/pubmed/32013232
http://dx.doi.org/10.3390/ijms21030865
_version_ 1783500469673394176
author Gaber, Timo
Brinkman, Antonia Clara Katharina
Pienczikowski, Justyna
Diesing, Karoline
Damerau, Alexandra
Pfeiffenberger, Moritz
Lang, Annemarie
Ohrndorf, Sarah
Burmester, Gerd-Rüdiger
Buttgereit, Frank
Hoff, Paula
author_facet Gaber, Timo
Brinkman, Antonia Clara Katharina
Pienczikowski, Justyna
Diesing, Karoline
Damerau, Alexandra
Pfeiffenberger, Moritz
Lang, Annemarie
Ohrndorf, Sarah
Burmester, Gerd-Rüdiger
Buttgereit, Frank
Hoff, Paula
author_sort Gaber, Timo
collection PubMed
description Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing. Janus kinase (JAK) inhibition with tofacitinib has been demonstrated to act as a potent anti-inflammatory therapeutic agent in the treatment of RA, but its impact on the fundamental processes of bone regeneration is currently controversially discussed and at least in part elusive. Therefore, in this study, we aimed to examine the effects of tofacitinib on processes of bone healing focusing on recruitment of human mesenchymal stromal cells (hMSCs) into the inflammatory microenvironment of the fracture gap, chondrogenesis, osteogenesis and osteoclastogenesis. We performed our analyses under conditions of reduced oxygen availability in order to mimic the in vivo situation of the fracture gap most optimal. We demonstrate that tofacitinib dose-dependently promotes the recruitment of hMSCs under hypoxia but inhibits recruitment of hMSCs under normoxia. With regard to the chondrogenic differentiation of hMSCs, we demonstrate that tofacitinib does not inhibit survival at therapeutically relevant doses of 10–100 nM. Moreover, tofacitinib dose-dependently enhances osteogenic differentiation of hMSCs and reduces osteoclast differentiation and activity. We conclude from our data that tofacitinib may influence bone healing by promotion of hMSC recruitment into the hypoxic microenvironment of the fracture gap but does not interfere with the cartilaginous phase of the soft callus phase of fracture healing process. We assume that tofacitinib may promote bone formation and reduce bone resorption, which could in part explain the positive impact of tofacitinib on bone erosions in RA. Thus, we hypothesize that it will be unnecessary to stop this medication in case of fracture and suggest that positive effects on osteoporosis are likely.
format Online
Article
Text
id pubmed-7037633
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70376332020-03-11 Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing Gaber, Timo Brinkman, Antonia Clara Katharina Pienczikowski, Justyna Diesing, Karoline Damerau, Alexandra Pfeiffenberger, Moritz Lang, Annemarie Ohrndorf, Sarah Burmester, Gerd-Rüdiger Buttgereit, Frank Hoff, Paula Int J Mol Sci Article Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing. Janus kinase (JAK) inhibition with tofacitinib has been demonstrated to act as a potent anti-inflammatory therapeutic agent in the treatment of RA, but its impact on the fundamental processes of bone regeneration is currently controversially discussed and at least in part elusive. Therefore, in this study, we aimed to examine the effects of tofacitinib on processes of bone healing focusing on recruitment of human mesenchymal stromal cells (hMSCs) into the inflammatory microenvironment of the fracture gap, chondrogenesis, osteogenesis and osteoclastogenesis. We performed our analyses under conditions of reduced oxygen availability in order to mimic the in vivo situation of the fracture gap most optimal. We demonstrate that tofacitinib dose-dependently promotes the recruitment of hMSCs under hypoxia but inhibits recruitment of hMSCs under normoxia. With regard to the chondrogenic differentiation of hMSCs, we demonstrate that tofacitinib does not inhibit survival at therapeutically relevant doses of 10–100 nM. Moreover, tofacitinib dose-dependently enhances osteogenic differentiation of hMSCs and reduces osteoclast differentiation and activity. We conclude from our data that tofacitinib may influence bone healing by promotion of hMSC recruitment into the hypoxic microenvironment of the fracture gap but does not interfere with the cartilaginous phase of the soft callus phase of fracture healing process. We assume that tofacitinib may promote bone formation and reduce bone resorption, which could in part explain the positive impact of tofacitinib on bone erosions in RA. Thus, we hypothesize that it will be unnecessary to stop this medication in case of fracture and suggest that positive effects on osteoporosis are likely. MDPI 2020-01-29 /pmc/articles/PMC7037633/ /pubmed/32013232 http://dx.doi.org/10.3390/ijms21030865 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gaber, Timo
Brinkman, Antonia Clara Katharina
Pienczikowski, Justyna
Diesing, Karoline
Damerau, Alexandra
Pfeiffenberger, Moritz
Lang, Annemarie
Ohrndorf, Sarah
Burmester, Gerd-Rüdiger
Buttgereit, Frank
Hoff, Paula
Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
title Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
title_full Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
title_fullStr Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
title_full_unstemmed Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
title_short Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing
title_sort impact of janus kinase inhibition with tofacitinib on fundamental processes of bone healing
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037633/
https://www.ncbi.nlm.nih.gov/pubmed/32013232
http://dx.doi.org/10.3390/ijms21030865
work_keys_str_mv AT gabertimo impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT brinkmanantoniaclarakatharina impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT pienczikowskijustyna impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT diesingkaroline impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT dameraualexandra impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT pfeiffenbergermoritz impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT langannemarie impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT ohrndorfsarah impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT burmestergerdrudiger impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT buttgereitfrank impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing
AT hoffpaula impactofjanuskinaseinhibitionwithtofacitinibonfundamentalprocessesofbonehealing